Growth Metrics

Dexcom (DXCM) Non-Current Deffered Revenue (2011 - 2012)

Dexcom (DXCM) reported Non-Current Deffered Revenue of $600000.0 for Q4 2012, up 100.0% year-over-year from $300000.0 in Q1 2012, and up 5.45% on a QoQ basis from $569000.0 in Q3 2012.

Dexcom (DXCM) has 2 years of Non-Current Deffered Revenue data on file, last reported at $600000.0 in Q4 2012.

  • Quarterly Non-Current Deffered Revenue rose 100.0% year-over-year to $600000.0 in Q4 2012, while the trailing twelve-month figure through Dec 2012 was $600000.0 (up 100.0% YoY) and the FY2012 annual result came in at $600000.0, up 100.0% from the prior year.
  • Non-Current Deffered Revenue rose to $600000.0 in Q4 2012 per DXCM's latest filing, from $569000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $834000.0 in Q1 2012 and bottomed at $300000.0 in Q4 2011.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 512.79 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Zimmer Biomet Holdings 16.17 Bn 15.75 Bn 1.51 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2012 600,000.00
Sep 30, 2012 569,000.00
Jun 30, 2012 702,000.00
Mar 31, 2012 834,000.00
Dec 31, 2011 300,000.00